ACHN Achillion Pharmaceuticals Inc.

3.03
+0.1  (+3%)
Previous Close 2.93
Open 2.93
Price To Book 1.58
Market Cap 420308495
Shares 138,715,675
Volume 867,873
Short Ratio
Av. Daily Volume 1,636,749

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

End of Phase 2 meeting 4Q 2019.
ACH-4471
C3 glomerulopathy (C3G)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178
Hepatitis C (HCV)
Phase 2 interim data due May 17, 2019.
ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)
End of Phase 2 meeting 4Q 2019.
ACH-4471
C3 glomerulopathy (C3G)
Phase 1 multiple ascending dose trial initiation announced January 31, 2019. To be completed 3Q 2019.
ACH-5228
Healthy volunteers

Latest News

  1. Why Is Achillion (ACHN) Up 25.6% Since Last Earnings Report?
  2. Achillion Meets Enrollment Target in Kidney Disease Studies
  3. Why Achillion Pharmaceuticals Stock Is Jumping Today
  4. Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy
  5. Achillion Completes Enrollment in Rare Blood Disorder Study
  6. Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial
  7. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Are Analysts Right About The Drop In Earnings?
  8. Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
  9. Achillion to Present at the Barclays Global Healthcare Conference
  10. Achillion Reports Fourth Quarter and Full Year 2018 Financial Results
  11. Why a Connecticut pharma firm moved its C-suite to Blue Bell
  12. Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market
  13. Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference
  14. Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  15. Achillion Appoints Brian Di Donato as Chief Financial Officer
  16. Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
  17. Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers
  18. Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
  19. Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
  20. Top Picks 2019- Achillian Pharmaceuticals ACHN